Novartis AG (NVS)

NVS on New York Consolidated

88.95USD
22 Aug 2014
Price Change (% chg)

$0.00 (+0.00%)
Prev Close
$88.95
Open
$89.24
Day's High
$89.34
Day's Low
$88.83
Volume
651,408
Avg. Vol
1,136,944
52-wk High
$91.66
52-wk Low
$72.24

NVS

Chart for NVS

About

Novartis AG provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and... (more)

Overall

Beta: 0.53
Market Cap (Mil.): $241,550.09
Shares Outstanding (Mil.): 2,706.19
Dividend: 2.76
Yield (%): 3.10

Financials

  NVS Industry Sector
P/E (TTM): 22.69 33.79 34.50
EPS (TTM): 3.92 -- --
ROI: 10.09 18.70 17.96
ROE: 14.16 19.28 18.65
Search Stocks

Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

21 Aug 2014

UPDATE 2-Lilly psoriasis drug impresses; battle nears with Amgen, Novartis

(Adds details on drug, rival drugs, new treatment approach)

21 Aug 2014

Deals of the day- Mergers and acquisitions

Aug 20 - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

20 Aug 2014

Novartis hands over experimental TB drugs in antibiotic pullback

ZURICH - Novartis has signed a licensing deal to hand over its experimental tuberculosis (TB) drugs to the Global Alliance for TB Drug Development, joining a growing Big Pharma retreat from antibiotics.

20 Aug 2014

UPDATE 1-Novartis hands over experimental TB drugs in antibiotic pullback

* Novartis move adds to Big Pharma retreat from antibiotics R&D (Adds detail, analyst, Novartis comment)

20 Aug 2014

Novartis licenses experimental tuberculosis drugs to TB Alliance

ZURICH, Aug 20 - Novartis said on Wednesday it had signed an a deal to exclusively license its experimental drugs for tuberculosis (TB) to the Global Alliance for TB Drug Development.

20 Aug 2014

Novartis to invest in Israel's Gamida Cell, could buy out company

JERUSALEM - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.

19 Aug 2014

Novartis to invest in Israel's Gamida Cell, could buy out company

JERUSALEM, Aug 19 - Swiss drugmaker Novartis has agreed to take a 15 percent stake in Gamida Cell, an Israeli developer of stem cell therapies, in a deal that could reach more than $600 million, Gamida's parent said on Tuesday.

19 Aug 2014

BRIEF-Novartis to showcase heart failure leadership at ESC congress with results on LCZ696

Aug 11 - Novartis AG : * Says to showcase heart failure leadership at ESC congress 2014 with

11 Aug 2014

Novartis loses new bid to dismiss U.S. lawsuit over kickbacks

NEW YORK - A Manhattan federal judge on Thursday said the U.S. Department of Justice may pursue most of its lawsuit accusing Novartis AG of civil fraud for allegedly using kickbacks to boost sales of drugs covered by Medicare and Medicaid.

07 Aug 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $103.10 -0.39
Pfizer Inc. (PFE.N) $28.92 +0.10
Merck & Co., Inc. (MRK.N) $59.17 +0.32
Roche Holding Ltd. (ROG.VX) CHF265.90 +0.10
Abbott Laboratories (ABT.N) $42.11 -0.21
Sanofi SA (SASY.PA) €79.43 -1.16
AstraZeneca plc (AZN.L) 4,418.00p +6.50
GlaxoSmithKline plc (GSK.L) 1,429.50p -5.00
Eli Lilly and Co (LLY.N) $62.32 +0.29
Bristol-Myers Squibb Co (BMY.N) $50.18 +0.19

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00
Provider: Reuters Investment Profile
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks